Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine by Sylvain Lamure, Sylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, Luc-Matthieu Fornecker, Bernard Drenou, Caroline Jacquet, Fatiha Merabet, Milena Kohn, Florence Quélin, Angela Jackson, Sylvain Choquet, Rémy Duléry, Yassine Taoufik, Caroline Besson, Caroline Besson

Subjects: Get full text

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study by Hovav Azuly, Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh-Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

Subjects: “…Anti-CD20…”
Get full text

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab by I. Jonušaitė, N. Giedraitienė, G. Kaubrys, R. Kizlaitienė

Subjects: Get full text